Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects

• Ngā kaituhi matua: Won Suk Choi (Author), Ji Yun Noh (Author), Joon Young Song (Author), Hee Jin Cheong (Author), Seong-Heon Wie (Author), Jin Soo Lee (Author), Jacob Lee (Author), Shin-Woo Kim (Author), Hye Won Jeong (Author), Sook-In Jung (Author), Yeon-Sook Kim (Author), Heung Jeong Woo (Author), Kyung Ho Kim (Author), Hun Kim (Author), Woo Joo Kim (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2017-07-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Background: The influenza B virus has two lineages; Yamagata and Victoria. The two lineages are antigenically distinct and it is difficult to expect cross-protection between the lineages. Actually, the mismatch between circulating influenza B viruses and vaccine strains has been occurred frequently....